ArticleJournal of cachexia, sarcopenia and muscle2025
Global Burden of Musculoskeletal Disorders in Adults Aged 50 and Over, 1990-2021: Risk Factors and Sociodemographic Inequalities.
Article in Journal of cachexia, sarcopenia and muscle, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Prevalence of osteosarcopenia in postmenopausal women: a systematic review and meta-analysis.Journal of endocrinological investigation · 2026Pooled it
- Coumarins in musculoskeletal health: a systematic review.Frontiers in nutrition · 2026Pooled it
- Associations between work ability and work participation after rehabilitation: a longitudinal multicentre cohort study.EULAR rheumatology open · 2026Article
- Cardiometabolic index as a predictor of sarcopenia in U.S. adults aged 20-59: results from a cross-sectional study.Clinics (Sao Paulo, Brazil) · 2026Article
- Prognostic nutritional index versus pragmatically operationalized GLIM criteria for predicting postoperative complications and recovery in spine surgery: a prospective cohort study.Frontiers in nutrition · 2026Article
- The risk factors and predictive nomogram for postoperative hypoalbuminemia in elderly patients undergoing hip arthroplasty.Frontiers in nutrition · 2026Article
- Cadmium-induced nucleus pulposus derived mesenchymal stem cells apoptosis via MAPK signaling pathway contributes to IVD degeneration.In vitro cellular & developmental biology. Animal · 2025Article
- Global Burden of Musculoskeletal Disorders in Adults Aged 50 and Over, 1990-2021: Risk Factors and Sociodemographic Inequalities.Journal of cachexia, sarcopenia and muscle · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAdults aged 50 and over are particularly vulnerable to musculoskeletal (MSK) disorders, with their impact expected to intensify as the global population ages. This study aims to comprehensively assess the global burden of MSK disorders among adults aged 50 and over from 1990 to 2021, as well as temporal trends, risk factors and sociodemographic inequalities.
methodsData were sourced from the Global Burden of Disease 2021 study. Temporal trends in age-standardized rates were evaluated by calculating average annual percent changes (AAPC). Absolute and relative inequalities were assessed using the slope index of inequality and concentration index, respectively.
resultsFrom 1990 to 2021, MSK disorders remained the largest contributor to total years lived with disability (YLDs) among adults aged 50 and over globally. The global age-standardized incidence rate significantly decreased (AAPC = -0.181, 95% CI: -0.190 to -0.172), whereas the global prevalence and disability-adjusted life-year (DALY) rates significantly increased (AAPC = 0.126, 95% CI: 0.118-0.134, and AAPC = 0.057, 95% CI: 0.042-0.072, respectively). High sociodemographic index (SDI) countries exhibited the highest age-standardized incidence, prevalence and DALY rates (11 236.6, 56 308.1 and 5277.1 per 100 000 population, respectively), whereas low-middle SDI countries showed the most rapid increases in prevalence and DALY rates (AAPC = 0.229, 95% CI: 0.218-0.240, and AAPC = 0.230, 95% CI: 0.204-0.256, respectively). Significantly positive associations were identified between SDI and age-standardized incidence, prevalence and DALY rates (all p < 0.001). High body mass index (BMI) was the largest contributor to global DALYs of MSK disorders, accounting for 10.3% of the total in this population, whereas occupational ergonomic factors, smoking and kidney dysfunction contributed 7.3%, 6.0% and 0.2%, respectively. Although the proportions of DALYs due to occupational ergonomic factors and smoking declined globally (from 9.2% to 7.3% and from 8.9% to 6.0%, respectively), those due to high BMI and kidney dysfunction increased (from 7.7% to 10.3% and from 0.19% to 0.22%, respectively). Both absolute and relative SDI-related inequalities persisted across 204 countries and territories, with no significant changes observed.
conclusionsMSK disorders have remained the largest contributor to disability among adults aged 50 and over. Despite significant progress in reducing the incidence rate, both the prevalence and DALY rates have significantly increased. With the expanding global ageing population, there is an urgent need for improved prevention strategies to mitigate the long-term impacts of MSK disorders in this vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.